|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Follistatin-related protein gene (FRP) is expressed in the synovial tissues of rheumatoid arthritis, but its polymorphisms are not associated with genetic susceptibility.
|
15638044 |
2005 |
|
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
|
Congestive heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
|
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term.
|
28178680 |
2017 |
|
Dyslipidemias
|
0.010 |
Biomarker
|
group |
BEFREE |
FSTL3 as adipokine takes part in dyslipidemia and inflammatory response, but the association of FSTL3 with atherosclerosis is unclear.
|
31815869 |
2019 |
|
Metabolic Syndrome X
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Activin A, activin B, follistatin, and FSTL3 were measured in (1) 80 subjects divided according to age (young vs old) and fitness status (active vs sedentary) before and after exercise at 70% maximal oxygen consumption (VO2max), followed by 90% of VO2max until exhaustion; and (2) 23 subjects [9 healthy and 14 with metabolic syndrome (MetS)] who completed four sessions: no exercise, high-intensity interval exercise, continuous moderate-intensity exercise, and resistance exercise for up to 45 minutes.
|
30085147 |
2018 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
|
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
|
Rheumatism
|
0.010 |
Biomarker
|
disease |
BEFREE |
As a result of this unique combination of the libraries and probes, we cloned follistatin-related protein (FRP) as a novel autoantigen in systemic rheumatic diseases.
|
9786430 |
1998 |
|
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
|
Fatty Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
|
Takayasu Arteritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Considering this, we further built a logistic regression model based on multiple cytokines, including CA (cancer antigen) 125, FLRG (follistatin-related protein), IGFBP (insulin-like growth factor-binding protein)-2, CA15-3, GROa (growth-regulated alpha protein), LYVE (lymphatic vessel endothelial hyaluronic acid receptor)-1, ULBP (UL16-binding protein)-2, and CD (cluster of differentiation) 99, with an area under the curve reaching 0.909 for discriminating TA activity status.
|
30645172 |
2019 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Expression levels of follistatin, follistatin-like 3, and activin subunits beta(A) as well as beta(E) were investigated in chemically induced rat and human liver tumours by real-time PCR and immunohistochemistry.
|
16935389 |
2006 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Finally, a strong expression of FLRG was observed in invasive breast carcinomas in contrast with the normal luminal epithelial cells in which FLRG was not detected.
|
17671190 |
2007 |
|
Diminished ovarian reserve
|
0.010 |
Biomarker
|
disease |
BEFREE |
Forty-eight transcripts were differentially expressed, including CXXC finger protein 5 (CXXC5), forkhead box C1 (FOXC1) (down-regulated in DOR) as well as connective tissue growth factor (CTGF), follistatin-like 3 (FSTL3), prostaglandin-endoperoxide synthase 2 (PTGS2) and suppressor of cytokine signaling 2 (SOCS2) (up-regulated in DOR).
|
22246450 |
2012 |
|
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Framingham 10-year stroke risk (FSRP-10) quantified CVD-RFs.
|
30980900 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that activin-induced growth inhibition is altered in FLRG-expressing breast cancer lines.
|
17671190 |
2007 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p<0.001) and with nuclear grade (p<0.01).
|
28178680 |
2017 |
|
Renal Insufficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
In both human CKD and AKD, renal dysfunction remained the strongest independent predictor of FSTL3 serum concentrations in multivariate analyses.
|
28339962 |
2017 |
|
Heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins.
|
30842316 |
2019 |
|
Congestive heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins.
|
30842316 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In more advanced stages, FSTL3 levels are higher in NASH compared to SS and, within NAFLD patients, in those with more severe lobular and portal inflammation.
|
31690932 |
2020 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
It was previously reported that follistatin-like 3(FSTL3), an activin A binding protein, contributes to the invasion and migration of trophoblast.
|
31810141 |
2020 |